Azitra, Inc. Overview
Pro stress-test →Azitra is an early-stage clinical biopharmaceutical company developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. The company represents a focused play on next-generation bacterial therapeutics targeting rare and difficult-to-treat dermatological conditions.
Strategic Profile
Pro stress-test →Azitra's pipeline includes ATR-12 for Netherton syndrome in Phase Ib trials, ATR-04 for chemotherapy-induced rash in Phase 1/2, and ATR-01 for ichthyosis vulgaris. The company has a collaboration with Bayer, which provides validation and potential commercialization support for its engineered microbiome approach.
Competitive Landscape
Pro stress-test →Azitra competes in the niche but growing live biotherapeutic and microbiome therapeutics space, with broader dermatology competition from larger pharma (Pfizer, GSK, Abbvie) and specialized dermatology biotech. The bacterial therapeutic approach differentiates it from conventional small molecule or monoclonal antibody competitors but faces regulatory and manufacturing complexity.
Industry Context
Azitra, Inc. operates in Biotechnology - Live Biotherapeutics / Dermatology.
Key facts
Founded: 2014 · Headquarters: Branford, Connecticut, US · Employees: 12